- Revance Therapeutics Inc (NASDAQ: RVNC) has reported topline data from JUNIPER Phase 2 study evaluating DaxibotulinumtoxinA for Injection to treat adults with moderate to severe upper limb spasticity.
- It is a neurological condition that affects the ability to move the arms and affects hands, fingers, wrist, forearm, elbow, and shoulder. It occurs most commonly after a stroke or brain injury.
- All three doses (250 units, 375 units, 500 units) demonstrated numerically higher than placebo ...
Full story available on Benzinga.com